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Introduction
Lyme disease is the most common arthropod-borne ill-
ness in the United States (1, 2). Outer surface protein
(Osp) A elicits immunity against Borrelia burgdorferi
infection and is being used as a human vaccine (3–6).
OspA antibody blocks spirochete transmission to the
vertebrate host by binding to B. burgdorferi within the
gut of engorging Ixodes scapularis ticks (7–10). Phase III
clinical trials demonstrate that vaccination with OspA
provides 80–90% protection against Lyme disease, and
vaccine failures are generally associated with low anti-
body responses to OspA in vaccine recipients (5, 6).
The temporal expression of ospA during the 
B. burgdorferi life cycle implies that OspA has a function
within the arthropod host. Uninfected larval ticks
acquire spirochetes while feeding on infected mice. 
B. burgdorferi produce OspA soon after leaving the ver-
tebrate host and entering I. scapularis, suggesting an
important role for OspA in vector colonization (7–10).
Within nymphal ticks, spirochetes abundantly express
ospA and remain in close association with the tick gut.
When nymphs engorge on a vertebrate host, B. burgdor-
feri in the gut rapidly multiply, and 70–80% of the
organisms clear OspA from their surface (7).
B. burgdorferi continues to repress ospA in the mam-
malian host. ospA mRNA is not readily detectable after
tick-borne transmission of spirochetes to mice but can
sometimes be found up to 14 days after syringe chal-
lenge of mice with OspA-producing B. burgdorferi
(11–15). ospA is also not usually expressed during human
infection. However, some individuals may develop
humoral and cellular OspA responses in early-stage dis-
ease (16–19), and immune responses to OspA have been
associated with chronic Lyme arthritis, indicating that
this antigen is present in some patients (20, 21). The
selective expression of ospA when B. burgdorferi goes into
and resides within I. scapularis and the subsequent gen-
eral downregulation of ospA when spirochetes exit the
tick gut suggest that OspA may play an important role
in B. burgdorferi colonization of the arthropod vector.
Methods
B. burgdorferi and I. scapularis: culture and cultivation
A clonal isolate of B. burgdorferi N40 that is infectious
and pathogenic in mice, and represents a prototypic 
B. burgdorferi sensu stricto organism, was used through-
out these studies (22). Spirochetes were cultivated in
Barbour-Stoenner-Kelly (BSK) II medium at 33°C (23).
B. burgdorferi 46047, a naturally occurring B. burgdorferi
sensu stricto isolate that lacks OspA (24), was also used
in some spirochete-OspA binding studies.
Mated adult female I. scapularis were collected in the
field. The egg mass was then laid in the laboratory.
Hatched larvae were fed on uninfected C3H mice to 
produce pathogen-free nymphs. All tick rearing was per-
formed in an incubator at 26°C with 85% relative humid-
ity and a 12-hour light/dark photo period regimen.
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Borrelia burgdorferi outer surface protein (Osp) A has been used as a Lyme disease vaccine that blocks
transmission: OspA antibodies of immune hosts enter ticks during blood feeding and destroy spiro-
chetes before transmission to the host can occur. B. burgdorferi produce OspA in the gut of unfed
Ixodes scapularis ticks, and many spirochetes repress OspA production during the feeding process.
This preferential expression suggests that OspA may have an important function in the vector. Here
we show that OspA mediates spirochete attachment to the tick gut by binding to an I. scapularis pro-
tein. The binding domains reside in the central region and COOH-terminus of OspA. OspA also
binds to itself, suggesting that spirochete-spirochete interactions may further facilitate adherence in
the gut. OspA-mediated attachment in the tick provides a possible mechanism for how stage-specif-
ic protein expression can contribute to pathogenesis during the B. burgdorferi natural cycle.
J. Clin. Invest. 106:561–569 (2000).
ELISA
Protein binding to the tick gut extract. Recombinant OspAs
from B. burgdorferi isolates 25015 and N40, and OspC
from B. burgdorferi N40, were expressed and purified in
their nonlipidated forms (25, 26, 27). OspA and OspC
were expressed either without a fusion partner or as
fusion proteins with glutathione transferase (after
which the fusion partner was cleaved using thrombin),
as described previously (15, 25, 26). OspA with muta-
tions in specific amino acids, produced using site-
directed mutagenesis (see later in this section), were
also expressed as a fusion partner with glutathione
transferase, and the fusion partner was subsequently
removed with thrombin. Overlapping 18- or 19-mer
OspA peptides were synthesized by A. Michel at the
University of Mons, Belgium. Peptides were solubilized
in DMSO and diluted in PBS. OspAs, OspA peptides,
OspC, or BSA was labeled with FITC from Molecular
Probes Inc. (Eugene, Oregon, USA). The extent of con-
jugation of FITC per molecule of protein was deter-
mined according to the manufacturer’s instructions.
One milligram of each FITC-labeled protein represents
34 pmol of OspA, 43 pmol of OspC, and 15 pmol of
BSA. One picomole of OspA, OspC, and BSA bound to
2, 2.4, and 6.8 pmol of FITC, respectively.
Guts from flat nymphal I. scapularis ticks were dissect-
ed in PBS and homogenized on ice with a Kontes micro-
homogenizer (VWR Scientific Products, West Chester,
Pennsylvania, USA). Salivary glands from nymphal ticks
were dissected in PBS and also homogenized on ice. One
gut extract equivalent (0.5 µg) of protein or 0.5 µg of sali-
vary gland protein extract per well was used to coat
microtiter plates (ICN Biomedical Inc., Costa Mesa, Cal-
ifornia, USA). Protein concentrations were determined
using the Bio-Rad Protein Assay Kit (Bio-Rad Laborato-
ries Inc., Hercules, California, USA). In some studies, the
tick gut extract (TGE) in PBS was incubated with a com-
bination of protease inhibitors (Sigma protease inhibitor
cocktail, catalog no. P 8340; Sigma Chemical Co., St.
Louis, Missouri, USA) to ensure that the potential release
of proteases from the intestine would not degrade a puta-
tive receptor. The Sigma cocktail contains inhibitors with
broad specificity for the inactivation of serine, cysteine,
aspartic proteases, and aminopeptidases. One hundred
microliters of each extract (5 µg/mL) in PBS was used to
coat the wells. As controls, plates were coated (100
µL/well) with 10 µg/mL of BSA, gelatin, or FCS in a sim-
ilar fashion. Plates were incubated overnight at 4°C, and
tightly covered with cellophane to prevent evaporation.
Plates were then washed three time with PBS with 0.05%
Tween 20 (PBS-Tween-20). Nonspecific sites were
blocked by incubating the TGE-coated wells with 15%
normal FBS for 2 hours at 37°C. Plates were then incu-
bated with 100 µL of FITC-labeled OspA, OspC, or BSA
protein (10 µg/mL) or OspA peptide (5 µg/mL) at 37°C
for 1 hour. A dose-response curve was also performed
using 100 µL of FITC-labeled OspA, OspC, and BSA at 5,
10, 20, and 40 µg/mL. The plates were washed three
times with PBS-Tween-20. Binding was detected using
anti-FITC IgG-horseradish peroxidase (Amersham
Pharmacia Biotech, Piscataway, New Jersey, USA) as a sec-
ondary reagent and TMB microwell peroxidase substrate
(KPL, Gaithersburg, Maryland, USA) was used for color
development. The OD was read at 450 nm at either 5 or
15 minutes. In most of the studies, the OD was measured
at 15 minutes, at which time the highest recorded values
usually ranged between 0.5 and 1.0. In some studies (see
Figures 1b and 3a), the OD values were recorded at 5
minutes because the values obtained with high concen-
trations of OspA approached the upper limits of detec-
tion of the assay.
Spirochete binding to TGE. To examine B. burgdorferi
binding to the tick gut, the prepared wells containing
TGE were incubated for 4 hours at 30°C with 107 B.
burgdorferi N40 per well in PBS-Tween 20 supplement-
ed with 5% FBS. Control wells were coated (100 µL/well)
with BSA (10 µg/mL) or FCS (10 µg/mL). Unbound
spirochetes were washed away using PBS-Tween. Then
a mouse mAb (mAb H9724) directed against FlaB (28)
was added to the wells at a dilution of 1:25 and incu-
bated for 1 hour at 30°C. Anti-mouse IgG-HRP (Sigma
Chemical Co.) was used as secondary reagent at a dilu-
tion of 1:2,000. TMB microwell peroxidase substrate
(KPL) was used for color development, and the OD was
read at 450 nm. In some experiments, spirochetes were
incubated in the presence of 50 µg/well OspA.
Additional studies were performed in an identical fash-
ion, except that PBS was used instead of PBS-Tween, in
order to minimize permeabilization of the outer mem-
brane. In these studies, a murine B. burgdorferi antisera
was used to detect spirochetes.
OspA-OspA binding. Microtiter wells were coated
overnight at 4°C with 10 µg/well of OspA from B.
562 The Journal of Clinical Investigation | August 2000 | Volume 106 | Number 4
Table 1
The overlapping synthetic OspA peptides 






















Single-letter abbreviations for the amino acid residues: A, Ala; C, Cys; D, Asp;
E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q,
Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
burgdorferi N40, OspA from B. burgdorferi 25015, or BSA
in PBS. Nonspecific sites were blocked with 15% FBS,
and the plates were probed with 100 µL of 10 µg/mL
FITC-labeled B. burgdorferi N40 OspA or B. burgdorferi
25015 OspA for 1 hour at 37°C.
Site-directed mutagenesis
The results suggest that conserved amino acids between
B. burgdorferi in the amino acid regions OspA85–103 or
OspA229–247 (see Figure 6d) may facilitate binding. There-
fore, six OspAs, designated M1, M2, M3, M4, M5, and
M6, which carry unique mutations in peptide sequence
OspA85–103 or OspA229–247 (Table 1), were created by site-
directed mutagenesis. The amino acid number and
sequence in single-letter abbreviation in wild-type B.
burgdorferi N40 and mutant OspAs are as follows, and
encompass all the conserved amino acids in these regions:
M1 (KVK85-87 to ∆EVE), M2 (DL93-94 to ∆AR), M3
(EVFK100-103 to ∆AVFA), M4 (K231 to ∆A), M5
(VF236-237 to ∆GS), M6 (TIT242-244 to ∆ANA).
A pGEX-2T–based vector was used to express wild-
type or mutant OspAs. Mutant OspAs were generated
using the QuickChange site-directed mutagenesis kit
(Stratagene, La Jolla, California, USA). The following
mutagenic primers were used, and the substitution of
codons or nucleotides is indicated by underlining and
boldfaced type, respectively. All the mutations were
confirmed by sequencing, and wild-type or mutant
OspAs were expressed, purified, and labeled with FITC
















Confocal microscopy and immunofluorescence
Five to ten midguts were dissected out from nymphal
ticks in 100 µL of PBS. The organs were cut into two
pieces and placed on silylated glass slides (PGC Scien-
tific, Gaithersburg, Maryland, USA) to enhance attach-
ment. Slides were washed twice with PBS, incubated
with PBS-Tween 20 with 5% FBS for 30 minutes at room
temperature, and then incubated for 1 hour at room
temperature with FITC-labeled OspA, OspC, or BSA (50
µL of 100 µg/mL of FITC-labeled protein). Samples
were subsequently stained with propidium iodide (50
µL of a 10 µg/mL solution) for 3 minutes at room tem-
perature, washed three times with PBS-Tween-20, and
mounted in glycerol for examination. The tissues were
viewed using a Zeiss LSM 510 scanning laser confocal
microscope equipped with an argon/krypton laser (Carl
Zeiss Inc., Thornwood, New York, USA). 
For immunofluorescence, B. burgdorferi (107 spiro-
chetes/mL) were suspended in PBS, and 10-µL
aliquots were placed on silylated glass slides and
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Figure 1
OspA binds to an I. scapularis TGE. (a) FITC-labeled (-F) OspA from
B. burgdorferi 25015 or N40, OspC from B. burgdorferi N40, and BSA
were used to probe TGE-coated wells. Bars represent the OD450 at 15
minutes (mean ± SD) from three experiments. (b) Dose-response
curves are presented for FITC-labeled OspA-N40, OspC, and BSA
binding to TGE. The OD450 was measured at 5 minutes (mean ± SD)
from three experiments. (c) FITC-labeled OspA from B. burgdorferi
N40 was used to probe TGE-coated, tick salivary gland extract–coat-
ed (SG), BSA-coated, gelatin-coated (G), and FCS-coated (FCS)
wells. In some studies, TGE was first treated with a protease inhibitor
cocktail (TGE-PI) before incubation with OspA. Bars represent the
OD450 at 15 minutes (mean ± SD) from three experiments.
allowed to air dry. Each slide was then washed three
times with PBS and probed with FITC-labeled OspA,
OspC, or BSA (50 µL of 100 µg/mL of FITC-labeled
protein). Using a conventional Zeiss Axioskop fluo-
rescence microscope, spirochetes in ten microscope
fields (100× objective) were examined.
Tick gut: fractionation, and treatment with lipase,
glycosidase, or trypsin
Centricon concentrator tubes (Amicon Inc., Beverly,
Massachusetts, USA) with different molecular mass
cutoffs (10, 30, 50, and 100 kDa) were used to separate
TGE into different-sized fractions. Equal amounts of
protein (0.5 µg) from the filtrate and retentate were
used to coat microtiter wells that were then probed
with labeled OspA as described for ELISA.
TGE was prepared as described, and equal aliquots
were incubated with either heat-inactivated (95°C for
10 minutes) or active lipase or glycosidases as follows:
wheatgerm lipase at 10 U/mL (Sigma Chemical Co.)
for 1 hour at 37°C; N-glycosidase F, endo-α-N-acety-
galactosaminidase, α-2-3,6,8-neuraminidase, β-1,4-
galactosidase, and β-N-acetylglucosaminidase treat-
ment according to a glycoprotein deglycosylation kit
(Calbiochem-Novabiochem Corp., San Diego, Cali-
fornia, USA). An equal aliquot of TGE was also incu-
bated with trypsin for 1 hour at 37°C at 10 µg/mL
(Sigma Chemical Co.) in the presence or absence of
20 µg/mL soybean trypsin inhibitor (Sigma Chemi-
cal Co.). After enzyme incubation, the TGE with inac-
tivated enzyme was coated onto microtiter plates and
probed with labeled OspA as described for ELISA. In
some studies, 0.5 µg of TGE was first used to coat the
microtiter plate wells, and then the plates were
washed with PBS and the nonspecific sites were
blocked by incubating with 15% FBS for 2 hours at
37°C. Then the wells were incubated with trypsin for
1 hour at 37°C (with and without presence of soy-
bean trypsin inhibitor). Plates were then probed with
labeled OspA.
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Figure 2
OspA directly binds to the I. scapularis gut. Direct binding of FITC-labeled OspA (a) to the intact unfixed tick gut was detected using confo-
cal microscopy. FITC-labeled OspC (b), FITC-labeled BSA (c), and FITC (d) were used as controls. After probing the tick gut with FITC-
labeled protein (shown in green), the tissues were stained with propidium iodide to localize the nuclei of the gut cells (shown in red). The
FITC and propidium iodide images were examined at ×630 and presented as a single image for clarity.
Figure 3
Effect of increasing OspA on OspA-TGE binding, and OspA-OspA binding. (a) OspA binding to TGE is not saturable. OD was measured at 5
minutes. (b) Effect of excess unlabeled OspA on the binding of labeled OspA to TGE. TGE was probed with FITC-labeled OspA and increasing
amounts of unlabeled OspA. These data represent the mean ± SD from three experiments. OD values were measured at 15 minutes. (c) Bind-
ing of OspA with OspA. OspA from B. burgdorferi N40, B. burgdorferi 25015, or BSA was probed with FITC-labeled OspA (25015-F, black bars;
or N40-F, gray bars). Bars represent the mean ± SD from three experiments. OD values were measured at 15 minutes.
Results
OspA adherence to a TGE was examined by ELISA. Bind-
ing of recombinant FITC-labeled OspA from B. burgdor-
feri N40, a prototypic B. burgdorferi sensu stricto isolate,
and B. burgdorferi 25015, an isolate that has an OspA
with variability in the epitopes involved in protective
immunity (27), was assessed. Both OspAs readily bound
to the TGE (Figure 1a). In addition, OspA bound to TGE
in a dose-dependent manner (Figure 1b). Other proteins,
such as BSA or B. burgdorferi OspC adhered poorly to the
TGE (Figure 1, a and b). The binding appeared to be spe-
cific because OspA bound only weakly to a tick salivary
gland extract and did not bind to BSA, gelatin, or anti-
gens in FCS (Figure 1c). Furthermore, initial treatment
of the TGE with a combination of proteases did not
influence OspA-TGE adherence (Figure 1c). OspA also
adhered directly to intact unfixed tick gut tissue, as
shown by confocal microscopy (Figure 2). In contrast
FITC-labeled OspC, FITC-labeled BSA, and FITC did
not bind to the tick gut (Figure 2).
The influence of increasing concentrations of OspA
on OspA attachment to TGE was then evaluated. The
binding of FITC-labeled OspA to the TGE was aug-
mented when increasing amounts of labeled protein
were added and could not be saturated (Figure 3a). In
Figure 3a, the OD was recorded at 5 minutes because
the value for 19.2 µg/well OspA reached the upper
limits of detection. At this interval, the OD for 1.2
µg/well OspA was only 0.3; however, this value
increases to 0.74 when the plates are incubated for 15
minutes, consistent with the data in Figure 1. A sim-
ilar pattern, with lower OD values, was apparent
when the amount of immobilized TGE was reduced
from 0.5 µg/well to 0.5 ng/well, and binding was no
longer detectable when 0.5 pg/well of TGE was used
to coat the plates (data not shown). The inability to
saturate OspA binding could be due to a ubiquitous
tick gut receptor or to OspA-OspA interactions. The
binding of labeled OspA to the TGE did not decrease
in the presence of excess unlabeled OspA, suggesting
that OspA bound to OspA (Figure 3b). OspA-OspA
interactions were therefore directly examined.
Labeled OspAs from B. burgdorferi 25015 or N40
specifically bound to unlabeled OspAs (Figure 3c).
Studies then assessed this phenomenon using whole
B. burgdorferi and the TGE. As expected, spirochetes
adhered to the TGE-coated, but not to BSA- or FCS-
coated, wells (Figure 4). Spirochete suspended in PBS
could be detected with the B. burgdorferi antisera,
whereas bacteria suspended in PBS-Tween were also
identified with the FlaB mAb. The addition of OspA
enhanced B. burgdorferi binding to the TGE, consis-
tent with the data on OspA attachment to the TGE
(Figure 4). In contrast, the addition of OspA did not
result in adherence of B. burgdorferi to BSA or FCS
(Figure 4). OspA binding to B. burgdorferi N40 was
then directly demonstrated by immunofluorescence
(Figure 5). OspA did not effectively bind to B. burgdor-
feri 46047 that lack OspA, further suggesting that the
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Figure 4
B. burgdorferi N40 binding to tick gut extract is enhanced in the pres-
ence of OspA. BSA-, FCS-, and TGE-coated wells were incubated
with 107 spirochetes per well in the absence or presence of OspA
(example, TGE + OspA). Spirochetes suspended in PBS-Tween were
probed with a FlaB mAb (black bars). Spirochetes suspended in PBS
were probed with B. burgdorferi antisera (gray bars). Bars represent
the mean ± SD from three experiments.
Figure 5
OspA directly binds to B.
burgdorferi. FITC-labeled OspA
(a) was used to directly probe B.
burgdorferi N40. FITC-labeled
OspC (b) and FITC-labeled BSA
(c) were used as controls to
probe B. burgdorferi N40. FITC-
labeled OspA was also used to
probe B. burgdorferi 46047, an
isolate that lacks OspA (d).
binding was specific for OspA (Figure 5). These data
demonstrated that B. burgdorferi OspA bound to itself
as well as to the tick gut.
The OspA epitope or epitopes that bind TGE were
then mapped using 20 overlapping peptides (Table 1).
The first 16 amino acids of OspA, which encode a sig-
nal sequence, were not included in the studies.
OspA85–103 and OspA229–247 strongly bound to the TGE,
and several other peptides (OspA17–34, OspA27–44, and
OspA217–234) demonstrated moderate binding (Figure
6a). These peptides did not bind to BSA- or serum-
coated wells (data not shown). OspA from B. burgdor-
feri N40 competed for binding with OspA85–103 and
OspA229–247 but not with the other three peptides, sug-
gesting that OspA85–103 and OspA229–247 contained
functional binding sites (Figure 6b). Similar results
were obtained when OspA from B. burgdorferi 25015
was used for competition (data not shown). To test
whether OspA85–103 and OspA229–247 adhered to the
same TGE site, competition studies were performed
using FITC-labeled OspA85–103 or OspA229–247 and
excess unlabeled OspA85–103 or OspA229–247. OspA229–247
strongly competed for binding with OspA85–103 but not
vice versa (Figure 6c). This suggests either that (a) the
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Figure 6
OspA epitopes involved in binding. (a) Relative binding of overlapping OspA peptides (100 µL of 5 µg/mL peptide) to TGE. The background
binding of FITC (F) to TGE has been indicated. The mean ± SD of three experiments is shown. (b) Inhibition of labeled OspA peptide bind-
ing to TGE by unlabeled OspA. TGE was probed with 100 µL of FITC-labeled OspA peptide (5 µg/mL) in the absence (black bars) or pres-
ence (white bars) of 250 µg/mL of unlabeled OspA. The mean ± SD of two experiments using OspA from B. burgdorferi N40 is shown. (c)
OspA229–247 and peptide OspA85–103 bind to the same site, or effectively inhibit binding of a second site, in the tick gut. TGE was probed with
20 µg/mL of FITC-labeled OspA85–103 or OspA229–247 in the absence (black bars) or presence of competitor, 1 mg/mL of unlabeled OspA229–247
or OspA85–103, respectively (gray bars). Control studies used BSA as a competitor (white bars). The mean ± SD of six experiments is shown.
(d) Amino acid polymorphism in OspA85–103 and OspA229–247. Comparison of the B. burgdorferi N40 and B. burgdorferi 25015 sequences (vari-
able amino acids are indicated by asterisks). Seventy-nine OspA sequences available in GenBank were aligned, and the strictly conserved
residues are presented in bold face. Single-letter abbreviations for the amino acid residues are indicated in Table 1.
Figure 7
Binding of OspAs with mutations within amino acids 85–103 or
229–247 to TGE. Site-directed mutagenesis was performed to gener-
ate OspAs, designated M1–M6 with substitution in amino acids that
are conserved between B. burgdorferi species within region 85–103 and
229–247 (Figure 6d). M1–M6 contain the following amino acid
replacements: M1 (KVK85–87 to ∆EVE), M2 (DL93–94 to ∆AR), M3
(EVFK100–103 to ∆AVFA), M4 (K231 to ∆A), M5 (VF236–237 to
∆GS), and M6 (TIT242–244 to ∆ANA). Binding of OspA and M1–M6
to TGE is depicted. B represents binding of OspA to BSA (control).
M1–M6 showed a similar degree of binding to BSA (data not shown).
Bars represent the mean ± SD from four experiments. AP < 0.001.
two peptides bind to the same site in the tick gut but
that OspA229–247 binds with a much higher affinity
than OspA85–103 or that (b) OspA229–247 can effectively
block the binding at a second site.
OspAs from B. burgdorferi N40 and 25015 were both
able to bind to TGE. The OspA85–103 and OspA229–247
sequences of these spirochetes were therefore com-
pared. Conserved amino acid positions within these
regions of B. burgdorferi N40 and 25015 may possibly
facilitate OspA adherence to the tick gut (Figure 6d).
Site-directed mutagenesis was accordingly used to
generate OspAs with amino acid substitutions in these
regions, for use in TGE binding assays. Six mutant
OspAs, three with substitutions in OspA85–103 and
three with alterations in OspA229–247, were created that
encompass all the conserved amino acids between B.
burgdorferi species (see Methods and Figure 6d). OspA
mutants M5 and M6, with replacements in amino
acids 236–7 or 242–4 of OspA229–247, respectively,
demonstrated significantly less (P < 0.001) binding to
TGE than did authentic OspA (Figure 7).
The OspA receptor in the tick was then partially
characterized. To determine the approximate molec-
ular mass of the ligand, size-separated fractions of
the TGE were used in ELISA. A ligand or ligand com-
plex greater than 100 kDa exhibited binding activity
(Figure 8a). To understand the biochemical nature of
the OspA binding moiety, the TGE was treated with
wheatgerm lipases, a variety of glycosidases (N-gly-
cosidase F, endo-—N-acetygalactosaminidase, α2-
3,6,8-neuraminidase, β1,4-galactosidase, and β-N-
acetylglucosaminidase), or trypsin. Heat-denatured
enzyme (in the case of lipases or glycosidases) or pro-
teolytic enzyme in the presence of specific inhibitor
(soybean trypsin inhibitor) served as controls. Lipase
or glycosidases did not affect OspA binding to the
TGE (data not shown). In contrast, pretreatment of
the TGE with trypsin markedly diminished OspA
adherence (Figure 8b). A similar reduction in OspA
binding was also observed when the TGE immobi-
lized on microtiter wells was treated with trypsin
(Figure 8b, lanes marked W). OspA therefore bound
to a high molecular mass protein, or protein receptor
complex, in the TGE.
Discussion
These data demonstrate that B. burgdorferi OspA specifi-
cally binds to a protein or proteins in the gut of I. scapu-
laris. Selective ospA expression as the spirochete enters
larval ticks may allow B. burgdorferi to adhere to and col-
onize the vector. Similarly, repression of ospA during tick
feeding may facilitate B. burgdorferi detachment from the
gut and migration to the salivary glands and ultimately
the vertebrate host. The weak binding of OspA to tick
salivary glands (Figure 1b) suggests that the tick recep-
tor that binds OspA may be present, at least at some
level, in this tissue as well. However, spirochetes that
migrate from the tick gut to the salivary gland rarely, if
ever, express ospA (7, 9, 10). Therefore, any degree of
OspA-salivary gland binding is not likely to be func-
tionally relevant. These studies also indicate that OspA-
OspA interactions may increase spirochete adherence in
the gut through self-binding, particularly at high B.
burgdorferi density, and this phenomenon may partially
explain the reported in vivo aggregation of B. burgdorferi
in the tick gut or on cell lines in vitro (29–33). The down-
regulation of OspA by spirochetes during the bloodmeal
may also facilitate dissemination to the tick salivary
glands and the host’s dermis by preventing the bacteria
from clumping to one another during transmission.
The crystal structure of OspA has recently been elu-
cidated and demonstrates that OspA229–247 extends
from β-strand 19 to 20 in the COOH-terminal barrel
sheet (34). Interestingly, Phe-237 and Ile-243, within
OspA229–247, are associated with a hydrophobic cavity
suggested to be a ligand-binding site, and protein fold-
ing brings residues 236–7 and 242–4 into close prox-
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Figure 8
Characterization of the tick gut receptor that binds OspA. (a) Binding
of OspA to different-sized TGE fractions. Tick gut extracts were sub-
jected to size fractionation using Centricon concentrator tubes with
molecular mass cutoffs of either 10, 30, 50, or 100 kDa. In each sep-
arate fractionation, black and gray bars represent the separated TGE
containing the smaller and larger material, respectively. The means ±
SD from two experiments are shown. (b) Effect of trypsin treatment on
OspA binding to TGE. TGE was treated with soybean trypsin inhibitor
(I), soybean trypsin inhibitor and trypsin (I + T), or trypsin (T). The
trypsin-treated and control TGEs were then used to coat microtiter
wells and probed with labeled OspA. The OD of the binding of labeled
OspA to BSA is also shown as a control (B). In an additional series of
experiments, marked “W,” TGE-coated microtiter wells were treated
with soybean trypsin inhibitor, soybean trypsin inhibitor and trypsin,
or trypsin. Bars represent the mean ± SD from three experiments.
imity (34). The site-directed mutagenesis studies (Fig-
ure 7) further suggest that this region of OspA229–247 is
important in OspA-TGE binding because substitu-
tions in amino acids 236–7 or 242–4 significantly
reduced the binding to OspA to TGE. The reduced
degree of binding could be due to the replacement of
amino acids that are directly involved in attachment,
or in the alteration of the structure of the putative
hydrophobic cavity that is the probable ligand binding
domain. The fact that OspA molecules are capable of
adhering to each other must also be taken into con-
sideration in the analysis of the mutagenesis studies.
The OspA mutants M5 and M6 may have even greater
defects in attachment to the tick gut because OspA-
OspA binding may mask a further decrease in OspA-
tick gut adherence. Nevertheless, the significant
decrease in binding of M5 and M6, with substitutions
in amino acids 236–7 and 242–4, further demonstrates
that the attachment of OspA to the tick gut is specific
and, at least in part, mediated by the putative binding
pocket in the COOH-terminus of the protein.
The role of OspA during mammalian infection is not
yet known; however, one report has suggested that OspA
may facilitate spirochete interactions with endothelium
(35). Given that ospA is not generally expressed during
human and murine infection, it is possible that OspA
does not have an important role in the vertebrate host.
Alternatively, reports have demonstrated ephemeral
OspA antibody and T-cell responses during early-stage
Lyme disease, and OspA responses have been identified
during chronic antibiotic-resistant Lyme arthritis, sug-
gesting that OspA may sometimes be present during
infection (16–21). One speculation from these efforts is
that OspA may play a role in persistent B. burgdorferi col-
onization of synovial tissue. Identification of the I. scapu-
laris ligand(s) that binds to OspA in the tick may provide
clues to additional ligands in the mammalian host that
could also potentially interact with this lipoprotein.
B. burgdorferi has exquisitely adapted to survive in both
the arthropod vector and vertebrate host, and we show
that OspA is a spirochete antigen that facilitates adher-
ence in I. scapularis. In the mammalian host, several
spirochete antigens are involved in attachment to the
host. For example, decorin-binding protein (Dbp) A
mediates that binding of B. burgdorferi to decorin, and
BBK32 promotes the binding of spirochetes to
fibronectin (36–38). In I. scapularis, B. burgdorferi resides
in specific locations during distinct intervals of infec-
tion, including the gut of unfed ticks and the salivary
glands of engorging tick, and it is possible that differ-
ent spirochete antigens assist in the colonization of dif-
ferent tissues within the vector. The present studies with
OspA were performed at 37°C, whereas the ambient
temperature in flat ticks is lower (20°C), and the tem-
perature in engorging ticks and mammals is closer to
37°C; therefore, it is likely that temperature and other
host factors can further influence specific B. burgdorferi-
vector/vertebrate interactions. Understanding the func-
tion of B. burgdorferi genes that are selectively expressed
throughout the spirochete life cycle, and the molecular
basis of vector–B. burgdorferi interactions, will expedite
new approaches to the control of Lyme disease and pro-
vide a model for other arthropod-borne infections.
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